Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 known ✓ | P35354 | 1/20 | 0.48 |
| ▸ | CA2 known ✓ | P00918 | 5/20 | 0.46 |
| ▸ | SIGMAR1 known ✓ | Q99720 | 2/20 | 0.40 |
| ▸ | GAA known ✓ | P10253 | 1/20 | 0.33 |
| ▸ | KCNH2 known ✓ | Q12809 | 1/20 | 0.32 |
| ▸ | IDO1 | P14902 | 4/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 5/20 | 0.46 |
| ▸ | CA9 | Q16790 | 4/20 | 0.42 |
| ▸ | CA12 | O43570 | 3/20 | 0.42 |
| ▸ | CA4 | P22748 | 1/20 | 0.42 |
| ▸ | CA6 | P23280 | 1/20 | 0.42 |
| ▸ | CA5A | P35218 | 1/20 | 0.42 |
| ▸ | CA7 | P43166 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1003203 | 0.97 | — | — | |
| SCHEMBL218054 | 0.80 | TDP1 (0.67) | IDO1CYP3A4LMNACYP1A2CYP2D6 | |
| Hydrochloric Acid SCHEMBL30096476 | 0.75 | TDP1 (0.53) | IDO1CYP3A4LMNACYP1A2CYP2D6 | |
| Hydrochloric Acid SCHEMBL31628644 | 0.75 | TDP1 (0.53) | IDO1CYP3A4LMNACYP1A2CYP2D6 | |
| SCHEMBL13928882 | 0.74 | IDO1 (0.46) | IDO1CYP3A4CYP1A2CYP2D6CYP2C19 | |
| Hydrochloric Acid SCHEMBL30583826 | 0.73 | TDP1 (0.50) | IDO1CYP3A4LMNACYP1A2CYP2D6 | |
| SCHEMBL4852769 | 0.71 | TDP1 (0.56) | IDO1CYP3A4LMNACYP1A2CYP2D6 | |
| SCHEMBL1306461 | 0.71 | L3MBTL1 (0.50) | IDO1CYP3A4CYP1A2CYP2C19CYP2C9 | |
| SCHEMBL4094372 | 0.71 | TDP1 (0.56) | IDO1CYP3A4LMNACYP1A2CYP2D6 | |
| Hydrochloric Acid SCHEMBL5148885 | 0.71 | ALDH1A1 (0.48) | IDO1CYP3A4LMNACYP1A2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120157662-A | Preparation method of GSH activated photocrosslinked RNA photosensitizer and anti-tumor therapeutic application | 大连理工大学 | 2025-06-17 | — | — | CN | claimed |
| CN-122079894-A | Preparation method of N-aryl pyrazole compound | — | 2026-05-26 | — | — | CN | disclosed |
| CN-121570586-A | Phototherapy nano-drug with mitochondria/STAT 3 protein double-site targeting function, and preparation method and application thereof | 安徽医科大学 | 2026-02-27 | — | — | CN | disclosed |
| CN-119569637-A | Method for synthesizing 2, 3-trimethyl indole quaternary ammonium salt by one-pot process | 中国乐凯集团有限公司 | 2025-03-07 | — | — | CN | disclosed |
| EP-3681877-B1 | PYRAZOLE DERIVATIVE COMPOUND AND USE THEREOF | HANMI PHARMACEUTICAL CO LTD (KR) | 2024-10-16 | — | — | EP | disclosed |
| US-20240217934-A1 | FLUORINE-CONTAINING PYRAZOLE COMPOUND AND PRODUCTION METHOD THEREFOR | UNIMATEC CO., LTD. (JP) | 2024-07-04 | — | — | US | disclosed |
| CN-118271303-A | Indole salt photosensitive dye and preparation method and application thereof | 河南师范大学 | 2024-07-02 | — | — | CN | disclosed |
| CN-114621121-B | Preparation method of camphorsulfonyl hydrazides compound, camphorsulfonyl hydrazides compound product and application of camphorsulfonyl hydrazides compound product | 南京林业大学 | 2024-03-29 | — | — | CN | disclosed |
| EP-4332092-A1 | FLUORINE-CONTAINING PYRAZOLE COMPOUND AND PRODUCTION METHOD THEREFOR | Unimatec Co., Ltd. (JP) | 2024-03-06 | — | — | EP | disclosed |
| CN-117402076-A | Preparation method of norbornenyl acid formylhydrazine compound, product and application thereof | 南京林业大学 | 2024-01-16 | — | — | CN | disclosed |
| WO-2009055828-A1 | NEW TETRACYCLIC COMPOUNDS | MEDIVATION TECHNOLOGIES, INC. (US) | 2009-04-30 | — | — | WO | disclosed |
| US-20080287423-A1 | Use of Azapaullones For Preventing and Treating Pancreatic Autoimmune Disorders | EVOTEC INTERNATIONAL GMBH (DE) | 2008-11-20 | — | — | US | disclosed |
| EP-1879591-A1 | USE OF AZAPAULLONES FOR PREVENTING AND TREATING PANCREATIC AUTOIMMUNE DISORDERS | DeveloGen Aktiengesellschaft (DE) | 2008-01-23 | — | — | EP | disclosed |
| WO-2006117221-A1 | USE OF AZAPAULLONES FOR PREVENTING AND TREATING PANCREATIC AUTOIMMUNE DISORDERS | DEVELOGEN AKTIENGESELLSCHAFT (DE) | 2006-11-09 | — | — | WO | disclosed |
| US-6391902-B2 | TREATMENT OF DISORDERS ASSOCIATED WITH SMOOTH MUSCLE CONTRACTION SUCH AS INCONTINENCE AND IRRITABLE BOWEL SYNDROME | AMERICAN HOME PRODUCTS CORPORATION | 2002-05-21 | — | — | US | disclosed |
| CN-1333774-A | Substituted benzofuranodindoles and indenoindoles as novel potassium channel openers | AMERICAN HOME PROD (US) | 2002-01-30 | — | — | CN | disclosed |
| US-20010047026-A1 | Substituted benzofuranoindoles and indenoindoles as novel potassium channel openers | AMERICAN HOME PRODUCTS CORPORATION | 2001-11-29 | — | — | US | disclosed |
| EP-1135393-A2 | SUBSTITUTED BENZOFURANOINDOLES AND INDENOINDOLES AS NOVEL POTASSIUM CHANNEL OPENERS | AMERICAN HOME PRODUCTS CORPORATION (US) | 2001-09-26 | — | — | EP | disclosed |
| US-6288099-B1 | COMPOUNDS SUCH AS 8-BROMO-10H-BENZO(4,5)FURO(3,2-B)INDOLE-1-CARBOXYLIC ACID USED TO TREAT DISORDERS ASSOCIATED WITH SMOOTH MUSCLE CONTRATION SUCH AS URINARY INCONTINENCE AND IRRITABLE BOWL SYNDROME | AMERICAN HOME PRODUCTS CORPORATION | 2001-09-11 | — | — | US | disclosed |
| WO-2000034285-A2 | SUBSTITUTED BENZOFURANOINDOLES AND INDENOINDOLES AS NOVEL POTASSIUM CHANNEL OPENERS | AMERICAN HOME PRODUCTS CORPORATION (US) | 2000-06-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240217934-A1 | FLUORINE-CONTAINING PYRAZOLE COMPOUND AND PRODUCTION METHOD THEREFOR | CYP2F1, CYP4F11, CYP51A1 | PTGS2 4187/4885CA2 4504/4885SIGMAR1 1916/4885 |
| US-20010047026-A1 | Substituted benzofuranoindoles and indenoindoles as novel potassium channel openers | KCNJ2, KCNN3, KCNN2 | PTGS2 995/4885CA2 793/4885SIGMAR1 1411/4885 |
| US-20080287423-A1 | Use of Azapaullones For Preventing and Treating Pancreatic Autoimmune Disorders | IAPP, RNASE1, AMY2A | PTGS2 3669/4885CA2 3913/4885SIGMAR1 4768/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.